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https://doi.org/10.1016/j.celrep.2021.109010SUMMARYAcute myeloid leukemia (AML) is caused by recurrent mutations in members of the gene regulatory and
signaling machinery that control hematopoietic progenitor cell growth and differentiation. Here, we show
that the transcription factor WT1 forms a major node in the rewired mutation-specific gene regulatory net-
works of multiple AML subtypes.WT1 is frequently either mutated or upregulated in AML, and its expression
is predictive for relapse. The WT1 protein exists as multiple isoforms. For two main AML subtypes, we
demonstrate that these isoforms exhibit differential patterns of binding and support contrasting biological
activities, including enhanced proliferation. We also show that WT1 responds to oncogenic signaling and
is part of a signaling-responsive transcription factor hub that controls AML growth. WT1 therefore plays a
central and widespread role in AML biology.INTRODUCTION
Acute myeloid leukemia (AML) is a hematological malignancy
that occurs as a consequence of genetic alterations (Papaem-
manuil et al., 2016). An individual AML has an average of five
recurrent mutations plus a variable number of less recurrent mu-
tations (Ley et al., 2013). Two to three of these mutations tend to
be true interdependent drivers of leukemogenesis, with other
mutations representing interchangeable co-operating mutations
or random events (Welch et al., 2012). Of these, the majority of
AMLs carry mutations conferring a block in hematopoietic differ-
entiation and enhanced self-renewal, typically in genes encoding
transcription factors (TFs) or epigenetic regulators plus at least
one that constitutively activates intracellular signaling indepen-
dent of growth factors. Signaling mutations tend to be acquired
as secondary mutations and allow for enhanced cell proliferation
and survival. The most common signaling mutations in AML are
internal tandem duplications (ITDs) in the transmembrane
domain of the receptor FLT3 (FLT3-ITDs) that cause its constitu-
tive activation (Hayakawa et al., 2000). The most common TF
mutations in AML are in the RUNX1/CBFb genes encoding for
Core Binding Factor, in particular the recurrent t(8;21) transloca-This is an open access article undtion that fuses the DNA-binding domain of RUNX1 to almost the
entire ETO (RUNX1T1) repressor protein, generating the onco-
genic fusion protein RUNX1-ETO (Erickson et al., 1992).
Normal hematopoietic cell differentiation originates from he-
matopoietic stem cells (HSCs) and involves the differential
expression of lineage-determining TFs. Gene regulatory net-
works (GRNs) consist of constitutive and signaling responsive
TFs and the genes that they bind to and regulate, which them-
selves may encode TFs. The binding of TFs to developmental-
stage-specific target genes therefore drives shifts in GRNs
from one progenitor cell type to the next until terminal differenti-
ation is reached (Goode et al., 2016). These finely balanced GRN
dynamics are disturbed once one of their essential components
is mutated and terminal differentiation cannot be properly
executed.
To investigate the relationship between AML subtypes and
leukemic GRNs, we recently conducted a multi-omics analysis
of seven AML subtypes defined by mutations in the genes en-
coding the TFs RUNX1/CBFb and C/EBPa, the growth factor re-
ceptor mutation FLT3-ITD, or Nucleophosmin 1 (NPM1) which
often co-occurs with FLT3 mutations (Assi et al., 2019b). Our an-
alyses demonstrated that depending on the type of mutation,Cell Reports 35, 109010, April 20, 2021 ª 2021 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. WT1 is essential for leukemic maintenance
(A) Schematic of WT1 structure and sites of alternate start sites and splice sites.
(B) Expression ofWT1mRNA in purified primary AML leukemic blasts with different mutational subtypes (data from Assi et al., 2019b). Error bars show standard
error of the mean.
(C) Results of the shRNA drop-out screen conducted by Martinez-Soria et al. (2019) forWT1. Log2 fold change of shRNA reads at the final time point relative to
initial time point in xenotransplantation, serial colony formation assays, or long-term culture.
(D) Schematic of doxycycline-inducible shRNA construct targeting WT1 or NTC (non-targeting control).
(legend continued on next page)






OPEN ACCESSleukemic blast cells from each AML subtype display a specific
GRN with TFs forming different network nodes and being con-
nected to other nodes as well as subtype specifically expressed
target genes. These analyses showed that each AML subtype
establishes its own cellular identity that differs from that of
normal cells, i.e., differentiation has gone ‘‘side-ways.’’ For
selected TFs forming prominent network nodes within an AML-
subtype-specific GRN, we showed that they consist of TFs/TF
families that are required for the maintenance of the leukemic
phenotypes of their own subtype but not others (Assi et al.,
2019a; Assi et al., 2019b). Moreover, they are not essential for
the growth of normal cells, highlighting an increased depen-
dency of cancer GRNs on specific pathways that could be ex-
ploited for therapeutic purposes. Importantly, our analysis also
found some TF families forming network nodes in more than
one AML subtype. Such TF families are of great interest for the
development of novel therapies, as they may regulate crucial
common downstream target genes or may themselves be tar-
gets for therapeutic interventions. However, to be able to go
along this path, the role of such factors in different AML subtypes
has to be studied in detail, using both molecular and system-
level approaches. One of these TF families consists of the
AP-1 family of TFs that forms a prominent network node in the
GRNs of all investigated AML subtypes which we showed to
be required for the in vitro and in vivo growth of cells from two
leukemic subtypes but not for normal cells (Assi et al., 2019b).
Another such network node is formed by the Zn2+-finger TF
Wilms tumor 1 (WT1). WT1 plays an important role in develop-
ment, as Wt1 null mice die at embryonic day 13.5 due to renal
and cardiac problems (Kreidberg et al., 1993). Even a deletion
of Wt1 in 6-week-old mice led to rapid death with renal failure
and bone and fat loss (Chau et al., 2011).
WT1 was first identified as a tumor suppressor gene that was
commonly mutated in Wilms’ tumor, a specific type of pediatric
renal cancer (Call et al., 1990), and is aberrantly expressed in a
variety of other cancers, such as those of breast, brain, and co-
lon. Functional validation of its role as an oncogene in Wilms’
tumor was shown by RNA interference whereby depletion
caused cell cycle arrest and apoptosis (Tuna et al., 2005).
WT1 biology and its impact on gene expression are highly com-
plex, as it is expressed as different isoforms that display
different splicing variants and encode proteins with different
functional properties (Moriya et al., 2008). WT1 has been shown
to interact with TET2 ,and its expression levels impact the
epigenetic landscape (Rampal et al., 2014; Wang et al., 2015).
WT1 also affects post-transcriptional processing of RNA, as it
localizes and interacts with RNA splicing factors (Larsson
et al., 1995) and is incorporated into functional spliceosomes
(Davies et al., 1998).(E and F) Number of colonies formed per 2,000 cells seeded in methylcellulose, no
(E) or primary CD34+ bone marrow cells from a healthy donor transduced with do
bars show standard deviation. Significance was determined using a two-tailed S
(G–I) Density plots of ATAC-seq peaks in a 2-kb window, ranked top to bottom
cells relative to doxycycline-inducible shNTC-transduced cells in FLT3-ITD prim
AML cells (I).
(J) Time course of cumulative cell count of Kasumi-1 cells transduced with one o
biological replicates, and error bars show standard deviation. Significance was dWT1 is mutated in about 10% of AML patients, conferring a
poor prognosis (Inoue et al., 1994), and is overexpressed in
90% of AML (King-Underwood et al., 1996) at both the RNA
and the protein level (Alanazi et al., 2020). The relapse-free sur-
vival of WT1-mutated AML patients is significantly impaired
(Hou et al., 2010). WT1 overexpression in AML correlates with
a worse relapse-free survival and response to chemotherapy in
AML (Barragán et al., 2004), and its expression has been used
to predict relapse in patients in remission (Inoue et al., 1994).
Based on these results, WT1 has been flagged as a therapeutic
target in different cancers. Recently, T cell receptor gene thera-
pies were developed and trialed on patients with AML targeting
WT1 epitopes, which prevented relapse (Chapuis et al., 2019).
However, mechanistically, little is known about how WT1 drives
a more aggressive AML and why it is upregulated. Gene expres-
sion data from WT1-mutated patients suggest a perturbation of
cell proliferation, but little more is known to date (Becker et al.,
2010). It is unclear whether WT1 is an essential factor for
leukemic maintenance in different AML subtypes, how WT1
mutant proteins alter cellular phenotypes, how it cooperates
with other oncogenes, which target genes are bound by it, and
whether the binding pattern and the impact on gene expression
differ between isoforms.
Here, we addressed these questions at the gene-specific and
system-wide level by studying the role of WT1 in two major AML
subtypes, namely, t(8;21) and FLT3-ITD.We identifiedWT1 bind-
ing sites and show that WT1 is an essential part of the GRN and
regulates the growth of both subtypes in an isoform-specific
fashion. Our work also demonstrates that WT1 is differentially
connected to other TFs within subtype-specific GRNs and im-
pacts different sets of genes. Most importantly, we show that
WT1 responds to oncogenic signaling, indicating that it is down-
stream of a rewired signaling network that maintains an aggres-
sive leukemic phenotype.
RESULTS
WT1 expression is required for the growth of two major
AML subtypes
The full-length protein WT1 spans 448 amino acids and harbors
multiple domains, including 4 Zn2+-finger domains at the
C-terminal end of the protein (Figure 1A; Hamilton et al., 1995).
Differential promoter usage and splicing generate several iso-
forms of the protein with potentially different functions. Of partic-
ular importance are the production of the WT1 KTS and
WT1 +KTS isoforms that differ in sequences between zinc fin-
gers three and four, which are generated by differential splicing
at exon 9, resulting in either the presence or absence of three
amino acids (lysine, threonine, and serine). This feature hasrmalized to the short hairpin NTC (shNTC) control using primary FLT3-ITD AML
xycycline-inducible shNTC or shWT1 (F). n = 3 biological replicates, and error
tudent’s t test.
by relative tag count of peaks from doxycycline-inducible shWT1-transduced
ary AML cells (G), primary CD34+ bone marrow cells (H), or t(8;21) primary
f two shWT1 or NTC plasmids, with or without induction of doxycycline. n = 3
etermined using a two-tailed Student’s t test. *p < 0.05, **p < 0.005.
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Figure 2. WT1 gene regulation and WT1 mutations
(A) UCSC genome browser screenshot showing promoter capture HiC interactions and ATAC-seq peaks at the WT1 locus in primary t(8;21), primary FLT3-ITD,
and healthy CD34+ bone marrow cells. Data from Ptasinska et al. (2019) and (Assi et al., 2019b)
(B) DNA sequence at the intron 8 open chromatin site and with highlighted transcription-factor-binding motifs.
(C) H3K27ac ChIP-qPCR enrichment of Kasumi-1 cells transduced with a CRISPRa vector targeted to intron 8; levels were normalized to the empty vector control
and to the PU.1 14-kb enhancer (positive control).
(D) Relative expression levels of WT1 mRNA normalized to GAPDH in Kasumi-1 cells transduced with vectors expressing CRISPRa targeted to the indicated
DHSs.
(E) Western blot showing WT1 and GAPDH protein expression in Kasumi-1 cells transduced with an empty vector or with sgRNA targeted to intron 8 DHS.
(F) Colony-formating ability in methylcellulose of 2,000 Kasumi-1 cells expressing CRISPRa targeted against the indicated WT1 DHSs and normalized to the
empty vector control.
(G) Time course of cumulative cell growth of Kasumi-1 cells expressing CRISPRa targeted against the indicated WT1 DHSs.
(legend continued on next page)






OPEN ACCESSfunctional consequences, as it leads to different DNA-binding
properties of WT1 (Bickmore et al., 1992; Laity et al., 2000).
WT1mRNA is not expressed in purified CD34+mobilized periph-
eral blood stem cells (PBSCs) but is overexpressed in purified
leukemic blasts of all AML subtypes that we have analyzed to
date (Figure 1B) and WT1 represents a network node in multiple
mutation-specific AML subtypes (Assi et al., 2019b). In our study,
we focused on the role ofWT1 in two AML subtypes that we have
extensively characterized at the multi-omics level, namely, the
t(8;21) and FLT3-ITD AML (Cauchy et al., 2015; Ptasinska
et al., 2014). Both AML subtypes display distinct GRNs (Figures
S1A and S1B). We have previously shown that knockdown of
WT1 expression in the context of an RNAi screen strongly affects
leukemic growth of t(8;21) cells in vitro and after xenotransplan-
tation in vivo (Martinez-Soria et al., 2019; Figure 1C). To examine
whether this was also true for primary cells from AML patients,
we transduced purified healthy-donor-derived CD34+ stem cells
and FLT3-ITD and t(8;21) AML blast cells with lentiviral vectors
expressing an short hairpin RNA (shRNA) targeted against all
isoforms of WT1 together with a non-targeting control shRNA
(Figures S1D and S1E). Knockdown of WT1 by using a doxycy-
cline-inducible shRNA (Figure 1D) led to a strong reduction
of colony-forming ability in FLT3-ITD (Figure 1E) but not
healthy CD34+ cells (Figure 1F). WT1 knockdown led to minor
changes in the accessible chromatin landscape in the three
samples, as measured by Assay for Transposase-
Accessible Chromatin using Sequencing (ATAC-seq) (Figures
1G–1I), with the t(8;21) AML showing the greatest loss of
ATAC-seq peaks (1,884 peaks) (Figure 1I). All primary AML cells
displayed significant changes in gene expression that are
described in further detail below.
Only a few model systems are available for studying t(8;21)
AML, and the generation of patient-derived xenografts (PDXs)
in mice from primary t(8;21) cells has proven to be very chal-
lenging (Sanchez et al., 2009; Sarry et al., 2011). We therefore
used the Kasumi-1 cell line for elucidating the molecular details
of howWT1 impacts leukemic growth, which is a well-character-
ized model of t(8;21) AML (Ptasinska et al., 2012, 2014, 2019).
Similar to FLT3-ITD primary AML cells, and in concordance
with the xenotransplantation experiments, Kasumi-1 cells dis-
played reduced cellular growth after transduction with two
different WT1 shRNA (Figures 1J and S1F) as well as reduced
clonogenicity (Figure S1G) and slightly increased apoptosis (Fig-
ure S1H). However, we did not observe a difference in the cell
cycle (Figure S1I). Taken together, our data demonstrate that
WT1 is required for leukemic growth and clonogenicity in two
different AML subtypes.
Upregulation of the endogenous and mutated WT1
distorts growth
We next examined whether altering the expression levels of
endogenous WT1 would impact the growth of Kasumi-1 cells.(H) Schematic showing where frameshift mutations were introduced in WT1.
(I) Time course of cumulative cell growth of Kasumi-1 cells with or without doxycyc
exons.
For all panels, n = 3 biological replicates, and error bars show standard deviatio
**p < 0.005.To this end, we targeted a CRISPR-Cas9-histone acetyltransfer-
ase p300 (CRISPRa) fusion protein to potential regulatory re-
gions of the endogenous WT1 locus. WT1 displays a number
of DNase I hypersensitive sites (DHSs) that indicate potential
cis-regulatory elements serving as guides to the design of guide
RNAs. Each of these sites interacts with the promoter in
leukemic cells, as determined by promoter capture Hi-C
(CHi-C) analysis of primary cells (Figure 2A; Assi et al., 2019b).
Previous work had identified an enhancer in intron 3 (Zhang
et al., 1997) that we also detected as a DHS in AML cells and
PBSCs. We also noticed DHSs in intron 8 and at the 30 end of
the gene that appeared to be specifically and reproducibly acti-
vated in primary AML but not in healthy cells (Figures 2A and
S2A). One DHS in intron 8 was of interest because it contained
motifs for the RUNX, ETS, and AP-1 family TFs (Figure 2B) that
are important nodes in AML-subtype-specific GRNs. Targeting
CRISPRa strongly increased histone H3K27 acetylation at
DHSs (Figure 2C), but the DHS in intron 8 was the only site where
targeting of CRISPRa led to an increase in WT1 protein and
mRNA levels (Figures 2D and 2E), colony-forming ability (Fig-
ure 2F), and cellular growth (Figure 2G). Targeting did not lead
to major changes in the cell cycle or apoptosis (Figures S2C
and S2D). Based on its dynamic nature and the absence of the
intron 8 DHS in normal CD34+ cells, we speculate that this
element responds to changes in the cellular environment associ-
ated with transformation, leading to an upregulation of WT1
expression and increased growth, thus enforcing the leukemic
phenotype. As a control, we also targeted CRISPRa to a
CTCF-bound DHS downstream of WT1 to show that any
changes in gene expression were not simply a consequence of
forced histone acetylation at a site that interacts with the
promoter.
WT1 is recurrently mutated in AML, and a number of different
mutations in different exons have been detected (Figure 2H). We
were interested to see whether these altered proteins would
modulate the growth of t(8;21) cells as well. We therefore trans-
duced Kasumi-1 cells with doxycycline-inducible constructs ex-
pressing proteins carrying frameshift mutations in exons 8 and 9
(Figure S2E) that truncated the protein at different Zn2+-finger
domains. The presence of the exon 8 mutation but not the
exon 9 mutation led to significantly increased growth and clono-
genicity and a decrease in apoptosis (Figure 2I; Figures S2G and
S2H) but had no effect on the cell cycle (Figure S2F).
WT1 is bound by RUNX1-ETO as well as RUNX1 at both the
intron 3 and 8 sites (Figure S2B). It was previously shown that
WT1 cooperates with RUNX1-ETO to cause a more aggressive
AML in mice (Nishida et al., 2006). We therefore examined to
what extent the expression of WT1 was dependent on the pres-
ence of RUNX1-ETO by knocking down its expression over a
period of 10 days (Figure S2I). RUNX1-ETO depletion led to dif-
ferentiation of such cells and a strong downregulation of WT1
(Figure S2J). However, although RUNX1-ETO depletion online induction of WT1mutant proteins carrying frameshift mutations in different
n. Significance was determined using a two-tailed Student’s t test. *p < 0.05,
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Figure 3. Different WT1 isoforms have contrasting roles in AML maintenance
(A) Ratio between expression of mRNAs encoding the WT1 +KTS and WT1 –KTS isoforms in purified primary patient CD34+ cells.
(B and C) Top: Schematic showing the doxycycline-inducible strategy of WT1 isoform expression. Kasumi-1 cells were transduced with doxycycline-inducible
WT1 isoforms. Bottom: Measurement of a time course of cumulative cell count (B) and of colony formation per 2,000 cells seeded in methylcellulose and
normalized to empty vector control (C).
(legend continued on next page)






OPEN ACCESSchromatin was complete in 2 days (Ptasinska et al., 2019), down-
regulation was delayed, indicating that WT1 responds to
changes in the GRN of differentiating cells rather than to the
lack of RUNX1-ETO binding.
WT1 contributes to oncogenesis in an isoform-specific
fashion and cooperates with other oncogenes
Different AML subtypes within our patient cohort express
different ratios of the WT1 -KTS and WT1 +KTS isoforms (Fig-
ure 3A). We therefore investigated whether the various WT1 iso-
forms and splice variants displayed a different ability to regulate
leukemic growth in a leukemic context. We first transduced
Kasumi-1 cells with constructs expressing various doxycy-
cline-inducible WT1 isoforms (Figure S3A; Figure 3B, top panel),
whereby we took great care to express the different proteins
equally and at physiological levels. In growth assays, we did
not see a difference between the long (promoter 1) and short
(promoter 2) isoforms ofWT1 but uncovered contrasting impacts
of WT1 proteins with (+KTS) or without the splice variant lacking
the KTS sequence (KTS) (Figure 3B). All WT1 proteins carrying
KTS stimulated growth, whereas all WT1 –KTS isoforms sup-
pressed growth. Although 17AA alternatively spliced isoforms
have been described as having anti-apoptosis effects in a variety
of cancer cell lines (Ito et al., 2006), we did not find such an effect
in AML cells. The same was true for clonogenicity that strongly
dropped after WT1 –KTS isoform overexpression (Figure 3C).
The WT1 -KTS isoform mediated a slight increase in apoptosis
(Figure S3B) and alterations in the cell cycle (Figure S3C). In
accordance with these features, expression of the gene coding
for the apoptosis regulator Caspase 9 CASP9 was upregulated
with both isoforms but was much stronger in WT1 –KTS cells
(Figure S3D).
Isoform expression differentially impacted on the differentia-
tion stage of the cells, asmeasured by the analysis of the expres-
sion of the stem cell marker CD34 (CD34), the monocytic CD11b
marker (ITGAM) (Figures 3D, 3E, and S3D), and of cellular
morphology (Figure S3E). We also examined how the different
isoforms cooperated with the transforming oncogene RUNX1-
ETO by inducing the expression of WT1 proteins in the presence
of a RUNX1-ETO-targeting small interfering RNA (siRNA) (siRE)
as well as control siRNA (siMM) (Figures 3D and 3E). The deple-
tion of RUNX1-ETO alone leads to the onset of cell differentiation
indicated by a downregulation of CD34 and an upregulation of
CD11b (Ptasinska et al., 2012). Again, induction of the two iso-
forms showed opposite effects; expression of theWT1 –KTS iso-
form in RUNX1-ETO-depleted cells enhanced differentiation,
whereas expression of the WT1 +KTS isoform counteracted
the effects of oncogene depletion.
We next tested these reagents in cultured primary AML cells
from patients. The expression of the WT1 –KTS isoform, but
not the WT1 +KTS isoform, had a strong impact on primary(D and E) Time course of mean fluorescence intensity changes of CD34 (D) a
doxycycline-inducible empty vector, WT1 +KTS, or WT1 –KTS and transfected w
(F and G) Relative colony-formation ability of primary FLT3-ITD AML cells (F) or
doxycycline-inducible empty vector, WT1 +KTS, or WT1 –KTS.
For all panels, n = 3 biological replicates ,and error bars show standard deviatio
**p < 0.005.FLT3-ITD cells (Figures 3F and S3F), with a reduction in col-
ony-forming ability, whereas normal cells were unaffected by
the expression of either isoform (Figures 3G and S3H). We also
used ATAC-seq to assess genome-wide chromatin accessibility
after expressing different WT1 isoforms. The expression of the
WT1 –KTS isoform but not the WT1 +KTS isoform led to altered
patterns of chromatin accessibility in primary FLT3-ITD and
t(8;21) AML (Figures S3I and S3J) but not in healthy CD34+ cells
(Figure S3K). In accordance with the previous result indicating
increased myeloid differentiation, ATAC peaks gained in the
presence ofWT1 –KTS show an increased enrichment of binding
motifs for the myeloid master regulator PU.1 (Li et al., 2001).
In summary, our data demonstrate that the presence or
absence of the KTS peptide and the ratio between the two iso-
forms have a profound impact not only on leukemic growth of
AML cells but also on the chromatin landscape, cellular differen-
tiation, and the cooperation with other oncoproteins.
The absence of the KTS peptide dramatically alters the
global WT1 binding pattern
Our next experiments addressed the genomic locations with
which WT1 interacted and whether the two isoforms bound to
different genomic targets. To this end, we performed global
chromatin immunoprecipitation sequencing (ChIP-seq) experi-
ments with cells transduced with lentiviral vectors coding for
WT1 –KTS and WT1 +KTS isoforms, in parallel with an empty
vector control, to measure binding of the endogenous WT1 pro-
tein. The expression of the WT1 –KTS isoform had no influence
on the expression of the WT1 +KTS isoform and vice versa
(Data S1).
ChIP-seq revealed binding of WT1 isoforms to several thou-
sand sites (Figure 4A; Figure S4A) with no isoform-specific pref-
erence for particular genomic regions. In concordance with its
in vitro behavior (Laity et al., 2000), the WT1 –KTS isoform
interacted with many more genomic sites than the WT1 +KTS
isoform. This result was reproduced in cell clones carrying con-
structs expressing versions of the WT1 –KTS isoform with an
hemagglutinin (HA)-tag fused their N terminus (Figure 4B;
Figure S5A). We observed no difference in binding behavior be-
tween the long and short WT1 –KTS isoforms, and we were un-
able to perform ChIP on versions of WT1 carrying a C-terminal
tag (data not shown). This result is in contrast to a previously
published study that reported that WT1 +KTS bound to more
binding sites than WT1 –KTS and that WT1 isoforms have a pref-
erence for different genomic locations (Ullmark et al., 2017). The
differences are likely due to the better quality of our data.
WT1 peaks were enriched for ETS/PU.1 and RUNX1 motifs
(Figure 4B) but sequences clustered apart from the sites bound
by cell-fate-deciding factors, including RUNX1-ETO (Figure 4D;
some data from Ptasinska et al., 2014, 2019). Based on these
data, we could derive a chromatin-based position weight matrixnd CD11b (E) surface marker expression in Kasumi-1 cells transduced with
ith siRNA against RUNX1-ETO (siRE) or a mismatch (siMM) control.
primary CD34+ bone marrow cells from a healthy donor (G) transduced with
n. Significance was determined using a two-tailed Student’s t test. *p < 0.05,
Cell Reports 35, 109010, April 20, 2021 7
(legend on next page)






OPEN ACCESS(PWM) for WT1 in AML cells (Figure 4C). As suggested by previ-
ous in vitro experiments (Rauscher et al., 1990), this sequence is
very similar to that of the EGR (early growth factor response) fac-
tor family with the exception of an obligatory adenine at position
9 that is more variable for EGR factors (but also includes the A as
an infrequent base). The WT1 motif also shows some overlap
with the Sp1 motif GGGG(C/A)GGGG. The enriched binding
motif identified here was the same for the WT1 –KTS and the
WT1 +KTS isoforms (Figure 4E).
To further characterize WT1-bound chromatin regions, we
determined the binding profiles of EGR1 and Sp1 by ChIP-seq
and aligned these signals with the WT1 peaks ranked according
to WT1 binding signal, together with ChIP-seq peaks of other
factors expressed in Kasumi-1 cells, for which data are available
from our lab (Ptasinska et al., 2019) and others (Ben-Ami et al.,
2013; Martens et al., 2012). On the same axis, we also aligned
ChIP-seq signals measured in Kasumi-1 cells for aligned WT1
sites with RNA polymerase II (RNA Pol II); the co-activator
p300; the Nuclear Receptor co-Repressor NCoR (Trombly
et al., 2015); the histone modifications H3K27Ac, H3K9Ac (Pta-
sinska et al., 2019), and H3K27me3 (Trombly et al., 2015). We
also determined the binding sites of the endogenous WT1 in pri-
mary cells of t(8;21) patients (Figure 4F) which demonstrated a
strong overlap of WT1 binding sites in the Kasumi-1 cell line
and in primary t(8;21) cells. WT1 binding sites were strongly
associated with Sp1 binding sites but showed a weaker co-
localization with EGR1 bound sites. WT1 co-localized with active
(p300 associated, H3 acetylated) and with Pol-II-associated re-
gions but not with polycomb (H3K27me3) and NCoR-bound
chromatin. No preferred co-localization with any of the other
measured factors was observed. We next examined the impact
of the expression of the two WT1 isoforms on open chromatin
patterns by using DNase I which gives a more refined cleavage
pattern and sharper peaks than ATAC-seq (Karabacak Calviello
et al., 2019). The expression of both isoforms changed the chro-
matin pattern and, interestingly, also the motif composition of
enriched peaks (Figures S4D and S4E). In concordance with
the activation of differentiation driven by the WT1 –KTS isoform,
we observed a strong enrichment of binding motifs for PU.1 in
1,742 open chromatin sites gained after induction (Figure S4D).
This result was not observed with the WT1 +KTS isoform, for
which we observed a loss of PU.1 motifs in 3,131 accessible
sites present before induction (Figure S4E). In addition, the onsetFigure 4. Identification and characterization of isoform-specific WT1-b
(A) Venn diagram showing the overlap between WT1 ChIP-seq binding sites in Ka
WT1), WT1 –KTS, or WT1 +KTS.
(B) Average profile plots of motif density relative to distance from ChIP peak cen
table of the frequencies of enriched TF binding motifs is shown alongside.
(C) De-novo-generated position weight matrix underlying WT1 binding together
(D) Heatmap showing hierarchical clustering of Pearson correlation coefficients of
factor ChIP-seq profiles.
(E) Average profile plots of motif density relative to distance from ChIP peak ce
WT1 +KTS together with the table of enriched motifs in these sites.
(F) Density plots of the indicated TF and histone modification ChIP-seq peaks wit
bottom, in Kasumi-1 cells. Also ranked beside them are WT1 ChIP-seq peaks in
(G) Density plots of WT1 ChIP-seq peaks in a 2-kb window, ranked top to bottom
ETO relative to no-doxycycline control in Kasumi-1 cells. Plotted alongside are e
For all panels, significance was determined by a binomial test for motif enrichmeof differentiation caused by the depletion of RUNX1-ETO after
expression of an inducible shRNA caused a reduction of WT1
binding sites and a redistribution of WT1 sites toward cis-ele-
ments enriched in PU.1 motifs (Figure 4G; Figure S4F).
Conversely, the overexpression of the WT1 –KTS and
WT1 +KTS isoforms caused a shift of RUNX1-ETO binding to-
ward sites with RUNX1 motifs (Figures S4F and S4G). Taken
together, our analyses show that the binding pattern of WT1 is
dependent on the presence of RUNX1-ETO and vice versa.
WT1-isoform-specific regulation of AML-subtype-
specific GRNs
We next determined the nature of gene expression changes in
Kasumi-1 cells and in purified primary patient-derived blast cells
after WT1 knockdown and expression of WT1 –KTS and
WT1 +KTS isoforms by using RNA sequencing (RNA-seq). Clus-
tering of the RNA-seq profiles of differentially expressed genes
showed extensive WT1-isoform- and cell-type-specific changes
(Figure 5A; Figure S5A). WT1 manipulation led to both up- and
downregulation of gene expression, with approximately one-
third of responsive genes being direct WT1 targets, which we as-
signed using our previously published CHi-C data (Ptasinska
et al., 2019; Figure 5B). When we examined gene expression
changes at WT1 target genes, the +KTS form showed more
gene repression that the KTS isoform, with its specific targets
being mostly associated with gene activation (Figure S5A).
Only a small number of direct WT1-bound genes were respond-
ing to WT1 knockdown (Figure 5C; Data S1). Interestingly, WT1
knockdown and RUNX1-ETO knockdown changed gene
expression in a similar fashion (Figure 5D), emphasizing that
the two genes operate in the same pathway. KEGG pathway
analysis (Kanehisa and Goto, 2000; Data S1) of the response
to isoform overexpression demonstrated a strong response to
overexpression of theWT1 –KTS isoform, with multiple signaling
pathways being upregulated, including differentiation-promoting
cytokine receptors such as Granulocyte-Macrophage Stimu-
lating Receptor (GM-CSFRa (CSF2R) or the main driver of
macrophage differentiation SPI1 (PU.1). Downregulated genes
includedMYC, which could explain the differentiation-promoting
ability of this isoform. Overexpression of WT1 +KTS affected
fewer pathways, with the exception of a downregulation of genes
involved in Ca2+ transport and signaling (CALM2) encoding for
Calmodulin or Ca2+-stimulated phosphatases (PPTs). A numberound sites in chromatin
sumi-1 cells transduced with doxycycline-inducible empty vector (endogenous
ter in Kasumi-1 cells transduced with a doxycycline-inducible empty vector. A
with that of EGR1 based on ChIP-seq experiments.
WT1 isoformChIP-seq sequence profiles and that of the indicated transcription
nter in Kasumi-1 cells transduced with doxycycline-inducible WT1 –KTS and
hin a 200-bp window, ranked by tag count of WT1 peak size going from top to
primary t(8;21) AML cells.
by relative tag count of peaks in doxycycline-inducible shRNA against RUNX1-
nriched motifs and tables of enriched motifs.
nt analysis.
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OPEN ACCESSof responsive targets were shared by the two isoforms, but
the effect of overexpression was not the same for all of them
(Data S2).
The analyses of the responses of primary t(8;21) and FLT3-ITD
AML cells toWT1 isoform overexpression identified both up- and
downregulated genes, withmultiple pathways being altered (Fig-
ures 5E–5G; Figure S5B; Data S3). Importantly, for both primary
cells and transduced Kasumi-1 cells, each AML subtype re-
sponded to overexpression differently. Changes in gene expres-
sion were directly associated with differences in the accessible
chromatin landscape (Figure S5C), with patterns clustering into
the same groups. In primary cells, we found barely any overlap
between cell types for the specific subsets of WT1-responsive
genes, but the number of responding genes was higher in
FLT3-ITD AML than in t(8;21) AML cells (Figures 5H and 5I;
Data S3). However, the two AML subtypes shared some WT1-
regulated pathways. The expression of genes involved in a
number of signaling pathways was changed, including the
interleukin-17 (IL-17) signaling pathway (Data S3), highlighting
a reprogramming of the signaling environment towards inflam-
mation (Iwakura et al., 2011).
The extensive collection of multi-omics data available from the
Kasumi-1 cell line allowed us to construct a GRN of TF encoding
genes, some of which are themselves subject to WT1 regulation
(Figure S6, bottom half). This GRN can be used to link down-
stream non-TF target genes that are bound by WT1 and were
more that 2-fold upregulated after WT1 KTS (Figure S6A) or
WT1 +KTS (Figure S6B) expression (Figure S6, top half). Some
of these target genes encode potential drug targets, such as
the PIM1 or FES kinases. These analyses clearly demonstrate
that WT1-regulated genes are connected within a network of
TF families that control signaling response (AP-1, ATF, IRF,
FOX, STAT, and NFAT families), growth (MYC-family and HLH
E-Box factors), hematopoiesis (RUNX1 and CBFb), and myeloid
differentiation (IRF, ETS, PU.1, and C/EBP TF families), high-
lighting the importance of extracellular signaling in understand-
ing leukemic phenotypes and the formidable complexity of pre-
dicting the response to therapeutic intervention.
WT1 binding is modulated by other TFs
Our data so far indicate that WT1 is part of a GRN that includes a
number of signaling-responsive factors. The most interesting
factor family in this context is the early growth-factor response
(EGR) TF family that previously has been shown to respond to
a number of different growth signals (Thiel and Cibelli, 2002)
and whose binding site bears strong similarity to that of WT1Figure 5. WT1 isoform expression produces distinct transcriptional sig
(A) Heatmap displaying hierarchical clustering of differentially expressed genes
empty vector, WT1 +KTS, or WT1 –KTS.
(B and C) Number of differentially expressed WT1 target or non-target genes
WT1 +KTS, or WT1 –KTS (B) or shWT1 (C).
(D) Heatmap with hierarchical clustering of differentially expressed genes (RNA-
course of RUNX1-ETO depletion ranked alongside genes up- or downregulated
(E–G) Heatmap showing hierarchical clustering of differentially expressed genes in
AML (F), andprimary bonemarrowCD34+ cells froma healthy donor (G), transduce
(H and I) Number of differentially expressed genes of the indicated cell types transd
shWT1 constructs (I).(Figure 4C). Bootstrapping analysis of binding motifs examining
the significance of their co-localization within a distance of 50 bp
demonstrated that WT1/EGR1 binding sites strongly overlapped
with Sp1 binding sites (Figure 6A) which was confirmed by
analyzing ChIP andmotif density data (Figures 6B–6E). The anal-
ysis of the actual binding sequences unveiled the presence of a
composite Sp/WT1/EGRmotif with a defined spacing (Figure 6F)
that could also be seen after a strand-specific analysis around
the WT1/EGR1 peaks, suggesting that the factors act together
by wrapping with their Zn2+ fingers around opposite strands (Fig-
ure 6G; Figure S7A). This feature was not seen with other factors,
such as ETS (Figure S7B). These data strongly suggest a com-
plex interplay of the three factors at their respective genomic
location, most of which are Pol-II-associated regions and pro-
moters that will merit future investigation.
Given the similarity of binding sites (Figures 6A and 6C), we
questioned whether EGR1 binding responded to changes in
WT1 expression levels by performing EGR1 ChIP-seq assays in
Kasumi-1 cells afterWT1 depletion (Figure 6H) and WT1 isoform
overexpression (Figure 6I). Our experiment demonstrates that
that WT1 perturbation yielded a complex response (Figures 6J
and 6K). After WT1 knockdown, we observed a redistribution of
EGR1 binding away from Sp1 sites as the cells differentiate,
even at shared sites (Figure 6H). However, the effect of WT1 iso-
form overexpression was drastic; when ranked alongside peaks
from cells transduced with an empty vector, more than 14,000
EGR1 peaks were lost after WT1 –KTS or +KTS isoform overex-
pression, with only 298 gained (Figure 6I), both at shared and
non-shared sites, indicating that the two proteins regulate each
other’s binding patterns in different ways. This finding is exempli-
fiedbyaSOCS3downstreamDHSand theCASP9promoter (Fig-
ures S7C and S7D). In addition, consistent with its ability to drive
cell differentiation, expression of WT1 KTS led to the appear-
ance of new EGR1 sites associated with PU.1 motifs (Figure 6I).
Based on data from Assi et al. (2019b) that are derived from
patients (digital DNase I footprinting and CHi-C data), we con-
structed an AML-specific sub-module of WT1 and EGR1-regu-
lated genes in primary FLT3-ITD/NPM1 and primary t(8;21)
AML (Figures S8A and S8B). This analysis showed that both
WT1 and EGR1 are auto-regulated and that WT1- and EGR1-
regulated genes are strongly interlinked with multiple targets
containing motifs for both factors. This includes genes encoding
important regulators, such as the apoptosis regulator BCL2 and
the TF NFIX, which we showed to be an important network node
for FLT3-ITD AML growth (Assi et al., 2019b). Another EGR1-
bound gene is FOXC1 that is an oncogene in its own rightnatures
from the RNA-seq of Kasumi-1 cells transduced with a doxycycline-inducible
from Kasumi-1 cells transduced with doxycycline-inducible empty vector,
seq) from Kasumi-1 cells transduced with RUNX1-ETO measured over a time
after expression of doxycycline-inducible shRNA against WT1.
the RNA-seq profiles from primary FLT3-ITD-mutated AML (E), primary t(8;21)
dwith doxycycline-inducible empty vector,WT1+KTS, orWT1 –KTSconstructs.
uced with doxycycline-inducible empty vector,WT1 +KTS, orWT1 –KTS (H) or
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OPEN ACCESS(Somerville et al., 2015) and that we also demonstrated to be an
important FLT3-ITD AML network node (Assi et al., 2019b). The
structure of this network suggested a signaling-dependent
crosstalk between the two genes.
We next performed perturbation experiments to interrogate
this module. In our primary patient FLT3-ITD AML culture, we
conducted a number of perturbation experiments that show
how oncogenic signaling and factor binding feed into WT1/
EGR1modules (Figures 7A–7C). We first treated primary cell cul-
tures with the clinically approved FLT3 inhibitor Quizartinib
(AC220) (Figure 7A) that repressed the expression of both genes.
We also inhibited the RUNX1-CBFb interaction with a specific
small molecule (Figure 7B) that abrogated RUNX1 DNA binding
(Illendula et al., 2016). Treatment led to a downregulation of
WT1 but not EGR1. Finally, we blocked all AP-1 activity by using
a dominant-negative FOS peptide (dnFOS) (Olive et al., 1997)
(Figure 7C) that again showed a strong downregulation of WT1
but not EGR1. Taken together, our data show (1) the highly dy-
namic behavior of WT1 and EGR1 expression as well as chro-
matin binding in response to perturbation of each other’s expres-
sion, (2) an important role of RUNX1 and AP-1 in regulating WT1
expression, and (3) an essential role of oncogenic signaling in
WT1/EGR1 upregulation.
DISCUSSION
WT1 overexpression is a marker for an aggressive type of AML
independent of the AML subtype. It is upregulated after AML
relapse and is a biomarker for relapse prediction, as it can be de-
tected in minimal residual disease (MRD) (Inoue et al., 1994). In
addition,WT1 expression in MRD is a biomarker for AML relapse
after post-allogeneic stem cell transplantation (Nomdedéu et al.,
2018). Our work is therefore of clinical importance as it provides
insights into how WT1 contributes to AML fitness and why it is
upregulated. We find that (1) WT1 is an important component
of AML maintenance within the GRNs of multiple subtypes of
AML but not in normal cells; (2) it acts in an isoform-specific
fashion; (3) specific mutants and isoforms, in particular
the +KTS isoform, drive increased growth; (4) its overexpression
causes aberrant growth, thus linking its expression to increased
fitness; (5) the upregulation of its expression is linked to onco-
genic signaling and early growth factor response gene action;
and (6) most importantly, its binding within chromatin changes
the expression of many different genes, but in an AML-sub-Figure 6. The interplay of WT1, EGR1, and Sp1 zinc finger transcriptio
(A) Bootstrapping analysis clustering the significance of co-localization of the ind
cells.
(B) Venn diagram showing the overlap between WT1 and Sp1 ChIP-seq binding
(C) Venn diagram showing the overlap between WT1 and EGR1 ChIP-seq bindin
(D and E) Average profile plot of ChIP coverage (D) and motif density (E) relative
(F) Extended HOMER motif search in WT1 or EGR1 ChIP-seq experiments show
(G) Average profile plot of strand-specific Sp1 motif frequency relative to distance
(H and I) Density plots of EGR1 ChIP-seq peaks in a 2-kb window, ranked top to
WT1 relative to the no-doxycycline control in Kasumi-1 cells (H) or doxycycline-in
depict the number of specific and shared peaks. Plotted alongside are enriched
(J and K) Average profile plots of EGR1 ChIP coverage in Kasumi-1 cells transdu
vector, WT1 –KTS, or WT1 +KTS (K).
For all panels, significance was determined by a binomial test for motif enrichmetype-specific fashion with little overlap in differentially expressed
genes between AML subtypes.
Our ChIP and gene expression data allow us to propose
models of AML-subtype-specific upregulation of WT1 in
response to external signals (Figures 7D and 7E). In t(8;21) cells,
WT1 is bound by RUNX1-ETO at the intron 3 enhancer and the
potential negative regulatory element at intron 8. The intron 3
enhancer is bound by a number of TFs, including AP-1 family
members, which, in turn, are dependent on the expression of
the fusion protein and are required for the expression of multiple
RUNX1-ETO targets (Frank et al., 1999; Martinez-Soria et al.,
2019; Ptasinska et al., 2019). WT1 positively auto-regulates itself
and is required for the elevated expression of EGR1, which is
also a target of RUNX1-ETO, and is regulated by signaling inmul-
tiple contexts. EGR1 binds toWT1 and thus is likely to modulate
WT1 expression in response to external signals as well, high-
lighting a complex interplay between the two factors. In t(8;21)
cells, the knockdown of RUNX1 expression has no effect on
the expression of WT1 (data from Ben-Ami et al., 2013). In
contrast, RUNX1 is part of the FLT3-ITD AML GRN, as its inhibi-
tion leads to WT1 downregulation and its own expression is
upregulated by the FLT3-ITD signal (Figure 7E), again demon-
strating that the gene is differentially wired within different
GRNs. In a similar vein, in FLT3-ITD AML, WT1 and EGR1 are
bound by multiple signaling responsive factors such as AP-1
and STAT5 (Cauchy et al., 2015) and gene expression responds
to oncogenic signaling. However, only WT1 responds to pertur-
bation by RUNX1/AP-1 inhibition in spite of EGR1 being a target
of both factors. Finally, EGR1 strongly responds to WT1 knock-
down, indicating that WT1 acts upstream of EGR1. We therefore
conclude that elevated growth factor signaling in leukemic cells
is a major reason for WT1 upregulation and also provides an
explanation for the worse prognosis in such patients, as WT1 it-
self drives the enhanced growth of leukemic cells. Indeed, acti-
vation of signaling plays a key role in growth and increasing
fitness in AML. In apparently healthy individuals, the detection
of mutations in signaling genes such as KRAS, NRAS, NF1,
JAK2, and CBL could predict the development of AML around
6 years later (Abelson et al., 2018). Activating KRAS mutations
have been demonstrated to confer increased competitive sur-
vival in xenotransplantation experiments (Burgess et al., 2017).
Furthermore, the acquisition of a FLT3-ITD mutation in a NPM1
mutant background accelerates the relapse time as compared
to the NPM1 mutation alone (Höllein et al., 2018). Finally, WT1n factors
icated TF binding motifs within 50 bp within WT1 ChIP-seq peaks in Kasumi-1
sites in Kasumi-1 cells.
g sites in Kasumi-1 cells
to distance from the WT1 peak center in Kasumi-1 cells.
ing a composite Sp:WT1/EGR1 motif.
from the EGR1 peak summit, in EGR1 ChIP-seq peaks from Kasumi-1 cells (I).
bottom by relative tag count of peaks in doxycycline-inducible shRNA against
ducible WT1 –KTS relative to the empty vector control (I). The bars on the side
TF binding motifs.
ced with shWT1 ± doxycycline (J) and Kasumi-1 cells transduced with empty
nt analysis.
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OPEN ACCESSmutations have been described to cooperate with FLT3-ITD mu-
tations in the development of a fully penetrant AML in vivo (Pron-
ier et al., 2018), again alluding to the clonal advantages conferred
by activated signaling.
Irrespective of the isoform, WT1 binding sites overlap with
RNA Pol-II-bound regions, indicating that it is intricately associ-
ated with mRNA synthesis. WT1 depletion leads to AML-sub-
type-specific changes in the cis-regulatory landscape. The mo-
lecular basis for these changes is the regulatory interplay of
WT1 with other TFs, in particular EGR family members. In
t(8;21) cells, WT1 binding responds to the depletion of RUNX1-
ETO, and the knockdown of either protein leads to similar
changes in the gene expression pattern, suggesting that both
reinforce each other’s action. WT1 can therefore be seen as an
essential part of an AML maintenance network. Our analysis
shows the nature and structure of such networks and how they
are connected. However, as outlined in the introduction, WT1
is likely to regulate gene expression at multiple levels, including
mRNA processing and stability. In this context, it is interesting
to note that WT1 binds to its own intron-exon boundaries (Fig-
ure S2B), including the 30 UTR. Experiments outside the scope
of this study are currently examining whether WT1 impacts
splicing and mRNA turnover of its own and other genes.
Although TFs were long considered ‘‘undruggable,’’ recent
studies have pointed toward several potential therapeutic strate-
gies targeting their activities. Direct inhibition of TF complexes is
exemplified by CBFb-RUNX1 complex inhibition (Illendula et al.,
2016; Figure 7B). An alternate strategy is to target encoding up-
stream regulators (Figures 7D and 7E) or downstream effector
genes (Figure S6, top half). Our findings demonstrate that WT1
would present an important subtype-independent therapeutic
target. The success of using T cell receptor therapies against
WT1, particularly in the post-allogeneic stem cell transplant
setting (Chapuis et al., 2019), raises expectations that its clinical
usewould be feasible. However, our finding that differentWT1 iso-
forms have contrasting biological activities in AML indicate that
caution is needed when designing therapeutic approaches that
may shift the isoform ratio. Our results also highlight the need to
account for the AML subtype, as the genomic response to WT1
overexpression and WT1 regulation differs between subtypes,
meriting efforts to understand how their signaling network is re-
wired to keep AML cells alive and how this feeds into the WT1/
EGR1 axis. The success of choosing the right target will depend
on a thorough understanding on the role of aberrantly
expressed/mutated TFs within a transformed GRN.Figure 7. WT1 and EGR1 regulatory modules in t(8;21) and FLT3/NPM1
(A) Dot plot of relative gene expression as determined by RNA-seq of WT1 and
inhibitor Quizartinib (AC220). Note that all experiments were done twice.
(B) Dot plot of relative gene expression as determined by RNA-seq ofWT1 and EG
or the RUNX1-CBFb inhibitor (Illendula et al., 2016).
(C) Dot plot of relative gene expression of WT1 and EGR1 of primary FLT3-ITD ce
FOS (dnFOS), as measured by RT-PCR.
(D)WT1 and EGR1 regulatory subnetwork specific for Kasumi-1 cells based on th
2012; Ptasinska et al., 2014), as well as perturbation experiments (dnFOS expr
Ben-Ami et al., 2013). RUNX1-ETO expression upregulates AP-1 (Martinez-Soria
knockdown slightly reduces EGR1 expression (this study).
(E)WT1 and EGR1 regulatory subnetwork specific for FLT3-ITD/NPM1-mutated A
et al. (2015), and the perturbation and ChIP experiments described here.STAR+METHODS
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Antibodies
Mouse anti-GAPDH Primary Abcam cat# ab8245; RRID:AB_2107448
Rabbit anti-WT1 Primary Abcam cat# ab89901; RRID:AB_2043201
Rabbit Anti-mouse HRP Secondary Abcam cat# ab97046; RRID: AB_10680920
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Critical commercial assays
Nucleobond spin kit Machery-Nagel cat# 740955
RNeasy Plus micro kit QIAGEN cat# 74034
TruSeq Stranded Total RNA Library Prep
Kit with Ribo-Zero kit
Illumina cat# 20020596
NEBNext Ultra II RNA library kit New England Biolabs cat# E7770S
KAPA Hyper Prep kit Roche cat#KK8500
QIAGEN MinElute Kit QIAGEN cat# 28604
QIAGEN spin miniprep kit QIAGEN cat# 27104
Nucleobond Xtra Midiprep kit Machery-Nagel cat# 740420.50
Experimental models: cell lines
Kasumi-1 DMSZ Cat#ACC 220; RRID: CVCL_0589
HEK293T DMSZ Cat#ACC 305; RRID: CVCL_0063





pTRIPZ Dharmacon cat# RHS4744
pENTR-GFP In House N/A
pCW57.1 Addgene plasmid #41393; RRID: Addgene_41393
LentiCRISPRv2 Addgene plasmid #52961; RRID: Addgene_52961
p300-dCas9 Addgene plasmid #83889; RRID: Addgene_83889
tat, rev, gag/pol and vsv-g plasmids Richard Mulligan
(Mostoslavsky et al., 2005)
N/A
Software and algorithms
Bowtie Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/bowtie2/manual.shtml
MACS 2 Zhang et al., 2008 https://github.com/macs3-project/MACS
DEseq2 Love et al., 2014 https://bioconductor.org/packages/
release/bioc/html/DESeq2.html
LIMMA Ritchie et al., 2015 http://bioconductor.org/packages/
release/bioc/html/limma.html
HOMER Heinz et al., 2010 http://homer.ucsd.edu/homer/index.html
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HiCUP Wingett et al., 2015 https://www.bioinformatics.babraham.ac.uk/projects/hicup/
GOTHiC Mifsud et al., 2017 http://bioconductor.org/packages/
release/bioc/html/GOTHiC.html
R scripting language N/A https://www.r-project.org/
Picard N/A http://broadinstitute.github.io/picard/
Bedtools Quinlan, 2014 https://bedtools.readthedocs.io/en/latest/
Cytoscape Shannon et al., 2003 https://www.cytoscape.org/.
Trimmomatic Bolger et al., 2014 https://github.com/timflutre/trimmomatic
UCSC Genome Browser Kent et al., 2002 https://genome.ucsc.edu/
STAR Dobin et al., 2013 https://github.com/alexdobin/STAR
Cufflinks Trapnell et al., 2010 http://cole-trapnell-lab.github.io/cufflinks/





Further information and requests for reagents and resources should be directed to, and will be fulfilled by the Lead Contact,
Constanze Bonifer (c.bonifer@bham.ac.uk).
Materials availability
The plasmids used in this study are available from the Lead Contact.
Data and code availability
All high throughput data (RNA-seq, ChIP-seq, ATAC-sec and DNase I-seq data) generated in this study are available at the NCBI
Gene Expression Omnibus (GEO) under the accession number GEO under accession number GSE153865. The published article in-
cludes AML patient RNA-seq and DNaseI-seq data from Assi et al., 2019b with GEO accession number: GSE108316.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and cell line culture
Kasumi-1 and Human Embryonic Kidney (HEK) 293T cells were purchased from DMSZ (Deutsche Sammlung von Mikroorganismen
und Zellkulturen) and periodically checked for Mycoplasma infection and their identity checked by Short Tandem Repeat analysis.
Cells were cultured in RPMI-1640 media (Kasumi-1) or DMEM (HEK293T) supplemented with 10% fetal calf serum (FCS) (GIBCO),
2mML-Glutamine and 100U/ml Penicillin and 100 mg/ml Streptomycin. All cells were grown in a humidified incubator with 5%CO2 at
37C.
Patient samples, purification and culture
AML and healthy patient blood or bone marrow were taken freshly from University Hospitals Birmingham with specific consent from
the patients and ethical approvals from the National Health Service Research Ethics Committee.
Following acquisition of the patient sample, mononuclear cells were immediately isolated using density gradient centrifugation us-
ing Lymphoprep (StemCell Technologies). CD34+ cells were purified using CD34+microbeads (Miltenyl-Biotech). Sorted CD34+ cells
were cultured in 90% StemSpan SFEM II (StemCell Technologies, 10% CD34+ expansion supplement (StemCell Technologies) and
175nM UM171 (StemCell Technologies). Cells were grown in a humidified incubator with 5% CO2 at 37
C.
METHOD DETAILS
Targeted myeloid sequencing panel
gDNA was extracted by phenol-chloroform extraction of DNA. 50ng of purified DNA was used for custommyeloid sequencing panel
library preparation (Illumina) and sequenced on aMiSeq (Illumina) in paired endedmode with 150 cycles for each of Read 1 and Read
2 to achieve around 5000x coverage. Bioinformatics analysis was performed using the TruSeq Amplicon app in BaseSpace (Illumina).
After demultiplexing, the software used a custom banded SmithWaterman aligner to align the reads against the human hg38
reference genome. The somatic variant caller then performed variant analysis for the specified regions. Mutations were called by




RNAwas extracted using the Nucleobond spin kit (Machery-Nagel) or in the case of very low input RNA extractions of < 10,000 cells,
the RNeasy Plus micro kit (QIAGEN) was used. Library preparation was performed using the TruSeq Stranded Total RNA Library
Prep Kit with Ribo-Zero kit (Illumina) for cell lines or the NEBNext Ultra II RNA library kit (New England Biolabs) for primary cells.
Then Illumina sequencing was performed on a NextSeq 550 (Illumina) run in paired-end mode for 75 cycles for each of read 1 and
read 2.
Raw RNA-seq reads were processed with Trimmomatic v0.36 (Bolger et al., 2014) in order to trim sequencing adaptors and low
quality bases. The processed reads were then aligned to the human genome (version hg38) using STAR (Dobin et al., 2013) with
default settings. Separate density profiles for the positive and negative strand were generated using bedtools (Quinlan, 2014).
Gene expression was measured as fragments per kilobase of transcript per million mapped reads (FPKM) values using Cufflinks
(Trapnell et al., 2013) and differentially expressed genes were extracted using the cuffdif function in cufflinks and limma R package
(Ritchie et al., 2015) and then were quantile normalized. Genes were considered as expressed with p value% 0.01 and FPKM greater
than 1 in at least one sample. Genes were said to be differentially expressed genes if there was at least 2-fold change in expression
between any two conditions under test. Once the differentially gene expression lists were identified, the FPKM values from cufflinks
were used for further analysis. The cuffquant function in cufflinks was used to generate cbx files, cuffquant was used for quantification
with a GTF file. GTF files were downloaded from the UCSC genome browser. Files in cbx format were used as input into cuffdiff and
cuffnorm functions.
Hierarchical clustering of RNA-Seq samples and replicates was done by first calculating the Pearson correlation value for each pair
of samples. The resulting correlation matrix was then hierarchically clustered using complete linkage clustering of the Euclidean dis-
tances, and finally plotted as a heatmap in R.
Kyoto encyclopedia for genes and genomes (KEGG) pathway enrichment was performed using clueGO tools (Bindea et al., 2009).
A gene was considered to be differentially expressed if it had a greater than 2-fold change between experimental conditions, and a
Benjamini-Hochberg adjusted p value < 0.05. The size of the nodes reflects the number of genes within the term. The color of nodes
reflects the enrichment significance of the terms. The network was laid out using Cytoscape (Shannon et al., 2003).
Splicing at the transcript isoform and differential splicing were identified using SUPPA2 pipeline (Trincado et al., 2018). SUPPA2 is a
tool to study splicing across multiple conditions and to generate transcript events and local alternative splicing events from an anno-
tation file in GTF format. Initially SUPPA2 was used to generate the ioi file which provides the set of all transcripts from that gene from
which the transcript relative abundance is calculated. For the generation of PSI (Percentage Spliced In) values, SUPPA2 reads the ioi
file generated and the expression file to calculate the PSI value for each of the events. Then SUPPA2 calculates the magnitude of
splicing change (DPSI) for all transcripts and provide a p value as a measure for its significance across multiple biological conditions,
using the different replicates per condition.
DNase-I hypersensitive site mapping
DNase I digestions were performed as previously described (Bert et al., 2007). Briefly cells were permeabilized in DNase I resuspen-
sion buffer (60mMKCl, 10 mM Tris pH 7.4, 15 mMNaCl, 5 mMMgCl2 and 300mM sucrose) and then DNaseI diluted in dilution buffer
(60mMKCl, 0.4%NP40, 15 mMNaCl, 5 mMMgCl2, 10 mMTris pH 7.4 and 2mMCaCl2 was added and incubated at 22
C for exactly
3 minutes. The digestion was terminated by adding cell lysis buffer (300 mM Sodium Acetate, 10 mM EDTA pH 7.4, 1% SDS and
1 mg/ml proteinase K). DNA was then purified using phenol-chloroform extraction. Optimally digested DNA then underwent library
preparation using the KAPAHyper Prep kit (Roche) and size-selected for 200-300 bp fragments. Libraries were sequenced on aNext-
Seq 550 (Illumina) and run in single-end mode for 75 cycles.
Raw DNaseI-seq reads were trimmed with Trimmomatic v0.36 (Bolger et al., 2014) and aligned to the human genome version hg38
genome using Bowtie version 2.3.1 using default parameters (Langmead and Salzberg, 2012). Next duplicate reads and reads not
uniquely aligned to chromosomal position were moved from aligned data using Picard v2.10.5. These filtered reads were used to
generate density profiles using the genomeCoverageBed function from bedtools (Quinlan, 2014). These tag densities were displayed
using the UCSC Genome Browser (Kent et al., 2002).
DHSs were called with MACS2 (Zhang et al., 2008) using the callpeak function (nomodel, call-summits and q = 0.005 parameters).
The resulting peaks were then filtered against the hg38 blacklist and simple repeat tracks from the UCSC table browser (Karolchik
et al., 2004) to remove any potential artifacts. Peaks were annotated to the nearest gene or using promoter Capture HiC data, where
available, from (Assi et al., 2019b). The CHi-C paired-end sequencing reads from two AML patients and healthy CD34+ cells were
aligned using the HiCUP pipeline (Wingett et al., 2015) against the human genome (hg38). Statistically significant interactions
were called using GOTHiC package (Mifsud et al., 2017) and HOMER software (Heinz et al., 2010). A merged set of significant inter-
actions were identified and then were used to annotate ATAC and ChIP peaks to their genes.
Clustering of DNase I-seq samples was carried out using themerged set of peaks. The number of reads that mapped to these sites
was counted in a 400bpwindow centered on the peak summit, and subsequently normalized to total sample size using DEseq2 (Love
et al., 2014). Pearson correlation coefficients were then calculated between each pair of DNase I-Seq samples using the log2 of the
normalized read counts, and then hierarchically clustered using Euclidean distance and complete linkage clustering of the correlation
matrix in R. A peak was considered to be differentially accessible if the fold-difference of the normalized tag count was greater than 2
between experiments.Cell Reports 35, 109010, April 20, 2021 e3
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OPEN ACCESSTo create read density plots, peaks were first ordered according to fold-difference. The read density in a 2kb window centered
on the peak summits was then calculated using from the bedGraph files produced by Homer using the annotatePeaks.pl file in
HOMER, using the options -size 2000 -hist 10 -ghist. These were then plotted as heatmaps using java TreeView v1.1
(Saldanha, 2004).
De novo motif analysis was performed on peaks using HOMER (Heinz et al., 2010), recording the top enrichedmotifs within 200 bp
from the peak summit. The annotatePeaks function in HOMER was used to find occurrences of motifs in peaks and known
motif position weight matrices (PWM) were used from the HOMER database or from ChIP-seq experiments. PWMs of motifs (iden-
tified by HOMER) that are relatively enriched in a set of specific DNase I-seq peaks were used to calculate motif enrichment. For a








where nij is the number of peaks in each subset j (j = 1,2,.) containing motif i (i = 1, 2,..,I), I is the total number of motifs used in the
test, and Mj the total number of peaks in each subset j (j = 1,2,.).
Motif co-localization clustering was performed as previously described (Ptasinska et al., 2014). A motif position search was done
within WT1 ChIP-seq peaks. The distance between the centers of each motif pairs was calculated and the motif frequency was
counted if the first motif waswithin 50bps distance from the secondmotif. Raw z-scoreswere calculated from themean and standard
deviation of motif frequencies observed in random sets using bootstrap analysis, peak sets with a population equal to that of the ChIP
peaks were randomly obtained from the merged DNase I-seq peaks of all samples peak sets. Motif search and motif frequencies
calculations were repeated 1000 times for each random set. A matrix was generated and Z-scores were displayed after hierarchical
clustering as a heatmap with R.
Assay for transposase accessible chromatin (ATAC)-seq
Omni ATAC-seq was performed as in Corces et al. (2017). Briefly, cells were washed in ATAC resuspension buffer (RSB) (10mM
Tris-HCl pH7.5, 10mM NaCl and 3mM MgCl2) and then lyzed for 3 minutes on ice in RSB buffer with 0.1% NP-40, 0.1%
Tween-20. Then the cells were washed with 1ml of ATAC wash buffer consisting of RSB with 0.1% Tween-20. Then the nuclear
pellet was resuspended in ATAC transposition buffer consisting of 25ml TD buffer and a concentration of Tn5 transposase
enzyme (Illumina) related to the number of input cells, 16.5 ml PBS, 5 ml water, 0.1% tween-20 and 0.01%digitonin and then incubated
on a thermomixer at 37C for 30 minutes. The transposed DNA was then amplified by PCR amplification up to ½ of maximum
amplification, as assessed by a qPCR side reaction. The library was purified and run on an Illumina Flow Cell in as per the DNase
I sequencing protocol. Bioinformatic analysis of ATAC-seq was performed as per DNase I seq analysis with a few exceptions: 1)
Bowtie2 was used with the parameter–very-sensitive-local. 2) Peak calling with MACS2 v2.1.1 used the settings–nomodel–
nolambda -B–trackline.
Chromatin immunoprecipitation (ChIP)-seq
Cells were crosslinked in 1% formaldehyde for 10 minutes before being quenched by 0.4 MGlycine. For EGR-1 ChIP, cells were also
double-crosslinked with Di(N-succinimidyl) glutarate (DSG) for 45 minutes. Cells were lysed for 10 minutes in cell lysis buffer (5 mM
PIPES pH 8.0, 85 mM KCl, 0.5% NP-40, 1:200 Protease Inhibitory Cocktail [PIC] before undergoing nuclear lysis for 10 minutes in
nuclear lysis buffer (50 mM Tris pH 8.0, 10 mM EDTA, 1% SDS, 1:100 PIC). Nuclei were then sonicated in a Bioruptor Pico (Diage-
node) until chromatin was sheared to a 200-600 bp fragment size and then diluted in blocking buffer (16.7 mM Tris pH 8.0, 167 mM
NaCl, 1.2 mM EDTA, 1.1% Triton X-100, 0.01% SDS and 1:100 PIC). 15 ul of Dynabeads G were pre-blocked for 2 hours at 4C with
blocking buffer consisting of 0.5%BSA, 30 mg glycogen and ChIP grade antibody at a suitable concentration, before being incubated
overnight 4C with the diluted chromatin. See Key resources table for details of antibodies used.
Then the beads were washed in sonication wash buffer (50 mM Tris pH 8.0, 10 mM EDTA, 1% SDS), twice in Buffer A (20 mM Tris,
pH 8.0, 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mMNaCl), twice in Buffer B (20 mM Tris, pH 8.0, 0.1% SDS, 1% Triton X-100,
2 mM EDTA, 150 mM NaCl), with Lithium buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 1 mM EDTA pH 8.0, 0.5% NP-40 and 0.5%
sodium deoxycholate). Beads were then washed once in 1xTE. Chromatin was then eluted in 100mM NaHCO3 and 1% SDS and
reverse crosslinked for 4-16 hours at 65C with 50 mg Proteinase K. DNA was then cleaned up with 1.8x SPRI beads. qPCR ampli-
fication of immunoprecipitated DNA was compared to input at several loci of putative protein binding sites as well as non-binding
sites to assess the success of ChIP. See Data S4 for qPCR primer sequences.
Immunoprecipitated DNA was then library prepped with the KAPA Hyperprep kit as described before, except with a 200-450 bp
size selection of the final library and Illumina sequenced as described before.
Reads from ChIP-Seq experiments were processed, aligned to the human genome and filtered in the same way as with DNase
I-seq experiments. Peaks from transcription factor ChIP-seq experiments were identified using MACS2 with default settings. These
peakswere then compared to theDNase I-seq or ATAC-Seq data, with only peaks that occurredwithin open chromatin regions being
retained for further analysis. To identify differential binding of transcription factors such as WT1, initially union of all peaks was con-
structed bymerging peaks that had summitswithin 100 bp of each other. The read density in these peakswas then retrieved using thee4 Cell Reports 35, 109010, April 20, 2021
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OPEN ACCESSannoatePeaks.pl function in HOMER and normalized as counts per million in R. Peaks that had a fold-difference of at least 2 were
considered to be differentially bound between experiments. The target genes for these peaks were identified by annotating each
peak to its closest TSS using the annotatePeaks.pl function in Homer or using promoter Capture HiC data, where available, from
Assi et al. (2019b) and Ptasinska et al. (2019). Motif enrichment analysis was performed as with DNase I-seq data.
Average profiles of ChIP-Seq data were constructed by first normalizing each of the alignment tracks as counts per million (CPM)
using the bamCoverage function in deepTools v3.2.0 (Ramı́rez et al., 2014). These were then plotted using the plotProfile function in
deepTools.
Transcription factor and gene regulatory network identification
A subset of transcription factor (TF) genes and a gene regulatory network were identified as described in Assi et al., (2019b). The gene
names for transcription factors in human were obtained from AnimalTFDB (Zhang et al., 2011). TFs and up or downregulated genes
were considered as nodes and the nodes colored according to their gene expression fold-change. Node shape implies whether a
gene is TF or a non TF gene. Node border color signifies whether the gene is either a RUNX1-ETO target or not. A directed edge
from TFa to TFb or up/downregulated genes indicates motif binding of a TFa to the locus of the TFb and the edge is prominently dis-
played if TFa binds to the locus at that stage. The edge is classified and color coded according to the significant of motif count
enrichment.
Motif count enrichment were defined as previously described in Assi et al. (2019b). Motifs were annotated to their related promoter
using CHi-C data. Motif search within footprint coordinates where performed using HOMER (Heinz et al., 2010). The number of motifs
per TF gene were counted and the significance of motif enrichment was identified using bootstrapping on random sampling, a
random set of mappedmotif were extracted from all union motif. After 1000 iterations the mean, standard deviation and the z-scores
are computed. Motif (TFa) is linked to gene or TFb with positive z-score values only.
siRNA knockdown
Cells were resuspended to a concentration of 15x106 cells/ml and transferred to a 4mmelectroporation cuvette. 200nMof siRNAwas
added to the cuvette and then cells underwent electroporation for 10 ms at 350V in a square wave electroporator. Electroporation
was repeated every 2 days. See Supplementary file 5 for a table of siRNA sequences.
Cloning of shRNA constructs
Custom linker A and linker B oligonucleotides were designed as in Dow et al. (2012) with sense and anti-sense sequences. See Sup-
plementary file 5 for a table of shRNA sense sequences. 100 pmoles of linker A and linker B were phosphorylated and annealed using
T4 Polynucleotide Kinase and a gradual cooling ramp from 95C to 25C. pTRIPZ (Dharmacon) was digested with XhoI and MluI re-
striction enzymes and then dephosphorylated with Calf Intestinal Alkaline Phosphatase. The oligonucleotides digested plasmid were
then ligated using T4 DNA Ligase. The annealed plasmid was then transformed into competent bacteria, grown in Lysogeny Broth
and underwent maxiprep using the Nucleobond Xtra Midiprep kit.
Cloning of overexpression constructs
WT1 isoform cDNA was a gift from Naohiko Seki, Chiba University, Japan (Moriya et al., 2008). Dominant negative FOS (dnFOS)
cDNA was a gift from Charles Vinson, National Cancer Institute, Bethesda, USA (Olive et al., 1997). The cDNA was amplified by
PCR using primers with SalI and NotI restriction enzyme overhangs and then digested with SalI-HF and NotI-HF. See Supplementary
file 5 for a table of PCR primers.
pENTR-GFP plasmid was digested with SalI and NotI and the larger 3925 bp fragment was gel extracted and then ligated to the
dnFOS orWT1 isoform using T4 DNA ligase. The ligated plasmids were then recombined in the tet-on plasmid pCW57.1 (David Root,
Addgene plasmid #41393) using Gateway technology. The recombined plasmid was then transformed into competent bacteria,
grown in Lysogeny Broth and underwent maxiprep using the Nucleobond Xtra Midiprep kit.
WT1 mutant cloning
WT1mutant expressing plasmidswere createdwith stop codons in exons 7, 8 or 9 by site-directedmutagenesis of pENTR-GFP-WT1
by PCR using primers. See Supplementary file 5 for a table of PCR primers. Then the plasmid was recombined into pCW57.1 and
amplified and maxiprep performed as before.
HA tagged WT1 cloning
AHA tagwas added to either the N-terminal end or C-terminal end ofWT1 by site-directedmutagenesis of pENTR-GFP-WT1 by PCR
using primers. See Supplementary file 5 for a table of PCR primers. Then the plasmid was recombined into pCW57.1 and amplified




LentiCRISPRv2 plasmid (Feng Zhang, Addgene plasmid #52961) and p300-dCas9 (Charles Gersbach, Addgene #83889) were
digested using RsrII and AgeI and the 6241bp bandwas gel extracted from p300-dCas9 and the 10495bp band from LentiCRISPRv2.
These two fragments were then ligated using T4 DNA ligase to give LentiCRISP-p300-Cas9, transformed into chemically competent
bacteria and amplified and maxiprep performed as before.
Linker A and linker B oligonucleotides of the following sequences but with BsmBI overhangs were annealed and ligated into
LentiCRISPR-p300-Cas9 using T4 DNA ligase, transformed into chemically competent bacteria and amplified and maxiprep. See
Supplementary file 5 for a table of CRISPR crRNA sequences.
Following lentiviral transduction of Kasumi-1 cells, cells were assessed for H3K27Ac deposition by the dCas9-p300 by ChIP-
qPCR. Enrichment was normalized to a known site of H3K27Ac deposition, the PU114 kb enhancer and to enrichment of the empty
vector control. See Supplementary file 5 for a table of ChIP qPCR primer sequences.
Lentiviral transduction
tat, rev, gag/pol and vsv-g plasmids were a gift from Richard Mulligan, Harvard medical school, USA (Mostoslavsky et al., 2005).
HEK293T cells were grown in adherent culture and transfected using calcium phosphate co-precipitation: five plasmids
(pCW57.1 with cDNA insert, tat, rev, gag/pol and vsv-g) were mixed with 250 mM Calcium Chloride and 2.5 mM HEPES. This
was then slowly added to a buffer consisting of 50 mM HEPES, 280 mM Sodium Chloride and 1.5 mM Na2HPO4 and incubated
at room temperature for 35 minutes and then promptly added dropwise to the plates of HEK293T cells. Viral supernatant was
then harvested after 24 hours and subsequently every 12 hours for 36 hours prior to concentration. Virus was concentrated using
a Centricon Plus-70 100kDa filter.
1x106 cells from a cell line or sorted CD34+ primary cells were mixed with concentrated viral supernatant and 8 mg/ml polybrene
before being spinoculated at 1500xg at 32C for 90 minutes. If the viral constructs contain a puromycin resistance cassette, cells
were then puromycin selected for 7 days or alternatively cells transduced with a lentivirus with a GFP cassette were sorted by
FACS on a FACS Aria Custom machine.
Colony formation assays
In the case of cell lines, 2000 cells were seeded into 1.1 mL of a pre-mix of 2.6%Methocult methylcellulose (StemCell Technologies),
20% fetal calf serum, 0.4 mM L-Glutamine, 25 mM HEPES and 40% Iscove’s Modified Dulbecco Medium with or without 2 mg/ml of
Doxycycline. Colonies were assessed and counted 10 days after incubation at 37C. In the case of primary cells, 2000 cells were
seeded into 1.1ml of Methocult Complete with or without 2 mg/ml of Doxycycline. Colonies were assessed and counted 14 days after
incubation at 37C.
Growth curves of cell lines
2.5x105 cells/ml were cultured in usual culturemedia. Cells weremixedwith an equal volume of 0.4% trypan blue. Live cells which did
not uptake trypan blue were counted and cells were split every 2 days to 2.5x105 cells/ml and 2 mg/ml of doxycycline was added
where appropriate.
Flow cytometry
All flow cytometry was performed on a CyAn ADP machine (Beckman Coulter) and analyzed on Summit 4.3 (Beckman Coulter). Cell
differentiation was assessed by antibody staining for the stem cell marker CD34-PE (Miltenyi Biotech, cat# 130-113-179) and the
differentiated myeloid cell marker CD11b-APC (Miltenyi Biotech, cat# 130-110-554). Apoptosis was assessed by using Annexin V
kits with Annexin V-FITC (BD Biosciences, cat# 556547) or Annexin V-APC (BD Biosciences, cat# 550474) in experiments in any cells
were already GFP positive. Cell cycle analysis to distinguish the G1, S and G2-M phases of the cell cycle was performed by analyzing
cellular DNA content as assessed by fluorescence from the DNA intercalating stain 7-aminoactinomycin D (7-AAD).
Cytospins
5000 cells were spun onto a slide at 800 rpm for 4 minutes using a cytospin 4 cytocentrifuge (Thermo Scientific). Cells were then
methanol fixed and stained with Wright-Giemsa stain.
Western blot
Protein extraction was carried out by lyzing cells in RIPA (Radioimmunoprecipitation assay) buffer. Protein was mixed with Laemmli
buffer and was denatured at 95C. The protein was then separated a 5%–20% Tris-Glycine-Extended gel in SDS-PAGE running
buffer (0.025 M Tris pH 8.3, 0.192 M glycine and 0.1% SDS). The protein was then transferred onto a nitrocellulose membrane which
was blocked with 10% milk before being incubated with a primary antibody diluted in 5% milk at 4C for at least 16 hours. See key
resources table for antibodies used. Following this, the membrane was incubated with the appropriate Horse Radish Peroxidase
(HRP) conjugated secondary antibody in 5% milk and the membrane developed using the Pierce Enhanced Chemiluminescence
kit (Thermo Scientific) and imaged on a Bio-Rad ChemiDoc XRS+.e6 Cell Reports 35, 109010, April 20, 2021
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If not indicated otherwise, all statistical comparisons were performed using two-sided Student’s t test.
Differential gene expression and differential chromatin accessibility analysis was carried out using Limma. A gene was considered
to be differentially expressed or differentially accesible if it had a greater than 2-fold change between experimental conditions, and a
Benjamini-Hochberg adjusted p value < 0.01.Cell Reports 35, 109010, April 20, 2021 e7
